Drug intelligence / Profile preview

Lactiplantibacillus plantarum strain 84-3

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactiplantibacillus plantarum strain 84-3 is a specific probiotic bacterial strain within the L. plantarum species, characterized by its ability to produce l-glutamine, which has been linked to improvements in glucose homeostasis and metabolic parameters in animal models of type 2 diabetes. Its therapeutic effect is mediated through activation of hepatic AMPK/PPARγ signaling pathways via its l-glutamine metabolite, which reduces serum inflammation, improves glucose tolerance, insulin resistance, and blood lipid levels. This strain-specific action distinguishes 84-3 from other L. plantarum strains, and suggests potential for preventive or therapeutic strategies for metabolic disorders such as type 2 diabetes[1].

Other names: L. plantarum 84-3

Targets

AMPK (Adenosine monophosphate–activated protein kinase)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on Lactiplantibacillus plantarum strain 84-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactiplantibacillus plantarum strain 84-3.

Explore the full profile